Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
| Revenue (Most Recent Fiscal Year) | $3.12B |
| Net Income (Most Recent Fiscal Year) | $1.14B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 14.17 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.29 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.81 |
| Pre-Tax Margin (Trailing 12 Months) | 40.96% |
| Net Margin (Trailing 12 Months) | 35.11% |
| Return on Equity (Trailing 12 Months) | 19.23% |
| Return on Assets (Trailing 12 Months) | 15.44% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 17.23 |
| Book Value per Share (Most Recent Fiscal Quarter) | $80.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $17.63 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 66.07M |
| Free Float | 65.06M |
| Market Capitalization | $13.86B |
| Average Volume (Last 20 Days) | 958.75 |
| Beta (Past 60 Months) | 1.02 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |